Aspen Technology (AZPN)
(Delayed Data from NSDQ)
$245.00 USD
-0.97 (-0.39%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $246.26 +1.26 (0.51%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$245.00 USD
-0.97 (-0.39%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $246.26 +1.26 (0.51%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum D VGM
Zacks News
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.
Inogen (INGN) Rises 127% Year to Date: What's Driving the Stock?
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock.
Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Palo Alto (PANW) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Palo Alto's (PANW) fourth-quarter fiscal 2024 results reflect growth across the Products, Services and Subscription segments.
The Zacks Analyst Blog Highlights Spotify, Aspen, Maplebear, Paramount Global and Seagate
by Zacks Equity Research
Spotify, Aspen, Maplebear, Paramount Global and Seagate are included in this Analyst Blog.
Masimo (MASI) Gets New Suitors for Its Consumer Business Sale
by Zacks Equity Research
Masimo (MASI) receives unsolicited requests from multiple entities for acquiring its consumer business. The company already received a non-binding term sheet confirmation from a third party in May.
Soft-Landing Hopes Resurface: Top 5 Momentum Stock Picks
by Nalak Das
We have narrowed our search to five stocks that have solid momentum. These are: SPOT, AZPN, STX,CART, PARAA.
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Aspen's (AZPN) DGM Software Continues to Gain Strong Momentum
by Zacks Equity Research
Aspen's (AZPN) Digital Grid Management software suite is witnessing healthy adoption as the world is transitioning toward more renewable energy resources.
Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks
by Zacks Equity Research
Despite improving product sales, Accuray (ARAY) reports mixed fourth-quarter fiscal 2024 results.
Stereotaxis (STXS) Receives European Approval for GenesisX
by Zacks Equity Research
Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.
Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View
by Zacks Equity Research
Cardinal Health's (CAH) fourth-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.
Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are concerning.
Aspen (AZPN) Q4 Earnings & Revenues Surpass Estimates, Up Y/Y
by Zacks Equity Research
Aspen's (AZPN) fourth-quarter revenues are driven by strong pipeline execution, high upstream market demand, DGM suite growth and notable MSC suite uptake despite chemical sector challenges
Compared to Estimates, Aspen Technology (AZPN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Aspen Technology (AZPN) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Aspen Technology (AZPN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Aspen Technology (AZPN) delivered earnings and revenue surprises of 13.94% and 8.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Aspen Technology (AZPN) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Aspen Technology (AZPN) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Why Is HubSpot (HUBS) Up 1.9% Since Last Earnings Report?
by Zacks Equity Research
HubSpot (HUBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aspen Technology (AZPN) Up 6.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Aspen Technology (AZPN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Aspen (AZPN) Q3 Earnings & Revenues Surpass Estimates, Up Y/Y
by Zacks Equity Research
Aspen (AZPN) reports solid fiscal third-quarter results driven by healthy performance across all revenue segments amid cautious consumer spending.
Compared to Estimates, Aspen Technology (AZPN) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Aspen Technology (AZPN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aspen Technology (AZPN) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Aspen Technology (AZPN) delivered earnings and revenue surprises of 28.79% and 10.51%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Insights Into Aspen Technology (AZPN) Q3: Wall Street Projections for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Aspen Technology (AZPN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.